{"id":3057,"date":"2016-06-22T06:30:00","date_gmt":"2016-06-22T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/"},"modified":"2016-06-22T06:30:00","modified_gmt":"2016-06-22T06:30:00","slug":"lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/","title":{"rendered":"Lungcancerpatient ges kemoterapi genom In Vivo Lung perfusion med STEEN Solution\u2122"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>STEEN Solution\u2122 anv\u00e4ndes f\u00f6r f\u00f6rsta g\u00e5ngen n\u00e5gonsin f\u00f6r att ge lokal leverans av ett kemoterapeutiskt medel till en patient som lider av metastatiskt lungsarkom genom In-Vivo Lung Perfusion (IVLP). Detta var ocks\u00e5 f\u00f6rsta g\u00e5ngen STEEN Solution\u2122 anv\u00e4ndes f\u00f6r att perfundera en lunga p\u00e5 In-Vivo, d.v.s. p\u00e5 en levande patient. Syftet med studien \u00e4r att bevisa s\u00e4kerhet och utv\u00e4rdera m\u00f6jligheten att anv\u00e4nda STEEN Solution \u2122 f\u00f6r att f\u00f6rb\u00e4ttra isolerad v\u00e4vnadsterapi.<\/strong><\/div>\n<p><span>Ett ledande sjukhus har nyligen inkluderat sin f\u00f6rsta patient i en klinisk pr\u00f6vning f\u00f6r att ge kemoterapi f\u00f6r patienter som lider av lungsarkom. Enligt uppgifter fr\u00e5n American Cancer Society 2016, ber\u00f6r mjukdelssarkom cirka 12 310 m\u00e4nniskor \u00e5rligen i USA och mer \u00e4n 4 990 amerikaner d\u00f6r varje \u00e5r av denna sjukdom. Av de patienter som utvecklar sarkom i extremiteter, kommer cirka 20 procent att f\u00e5 isolerade lungmetastaserande n\u00e5gon g\u00e5ng under sin sjukdom. Kirurgi \u00e4r det b\u00e4sta s\u00e4ttet att behandla lungsarkom men p\u00e5 grund av mikrometastaser, som inte kan ses, har dessa patienter en risk som \u00e4r st\u00f6rre \u00e4n 70 procent att drabbas av \u00e5terfall efter denna operation. Anv\u00e4ndningen av systemisk kemoterapi har inte anv\u00e4nts hittills p\u00e5 grund av de signifikanta biverkningarna som ofta \u00e4r p\u00e5f\u00f6ljden. Med anv\u00e4ndningen av in-vivo lung perfusion kan kirurgen st\u00e4nga av lungan fr\u00e5n den systemiska cirkulationen och ge kemoterapi endast till lungan f\u00f6r att inte p\u00e5verka resten av kroppen. <\/span><\/p>\n<p><span>\u201dDetta \u00e4r ett viktigt steg fram\u00e5t i att utveckla m\u00f6jligheten till anv\u00e4ndning av IVLP i cancerterapi. Doseringen av kemoterapi f\u00f6r att ge optimal behandling med reducerade biverkningar \u00e4r \u00e4nnu inte helt klarlagt, men detta \u00e4r b\u00f6rjan p\u00e5 ett nytt kapitel inom cancerbehandling\u201d s\u00e4ger XVIVO Perfusions VD Magnus Nilsson. <\/span><\/p>\n<p><span>G\u00f6teborg 22 juni 2016<br \/><\/span>XVIVO Perfusion AB (publ)<\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, tel: +1\u00a0720\u00a0616 2101, e-post: christoffer.rosenblad@xvivoperfusion.com<br \/>Magnus Nilsson, VD, tel: 031-788 21 50, e-post: magnus.nilsson@xvivoperfusion.com<\/span><\/p>\n<p><span>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/span><\/p>\n<p><span>Informationen l\u00e4mnades f\u00f6r publicering den 22 juni 2016 kl. 08:30.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>STEEN Solution\u2122 anv\u00e4ndes f\u00f6r f\u00f6rsta g\u00e5ngen n\u00e5gonsin f\u00f6r att ge lokal leverans av ett kemoterapeutiskt medel till en patient som&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3057","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lungcancerpatient ges kemoterapi genom In Vivo Lung perfusion med STEEN Solution\u2122 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lungcancerpatient ges kemoterapi genom In Vivo Lung perfusion med STEEN Solution\u2122 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"STEEN Solution\u2122 anv\u00e4ndes f\u00f6r f\u00f6rsta g\u00e5ngen n\u00e5gonsin f\u00f6r att ge lokal leverans av ett kemoterapeutiskt medel till en patient som...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\\\/\",\"name\":\"Lungcancerpatient ges kemoterapi genom In Vivo Lung perfusion med STEEN Solution\u2122 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2016-06-22T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lungcancerpatient ges kemoterapi genom In Vivo Lung perfusion med STEEN Solution\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lungcancerpatient ges kemoterapi genom In Vivo Lung perfusion med STEEN Solution\u2122 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/","og_locale":"en_US","og_type":"article","og_title":"Lungcancerpatient ges kemoterapi genom In Vivo Lung perfusion med STEEN Solution\u2122 - XVIVO","og_description":"STEEN Solution\u2122 anv\u00e4ndes f\u00f6r f\u00f6rsta g\u00e5ngen n\u00e5gonsin f\u00f6r att ge lokal leverans av ett kemoterapeutiskt medel till en patient som...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/","name":"Lungcancerpatient ges kemoterapi genom In Vivo Lung perfusion med STEEN Solution\u2122 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2016-06-22T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/lungcancerpatient-ges-kemoterapi-genom-in-vivo-lung-perfusion-med-steen-solution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Lungcancerpatient ges kemoterapi genom In Vivo Lung perfusion med STEEN Solution\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}